X

Trial Profile

CS-866DM phase 3 clinical study: A double-blind controlled trial in patients with diabetic nephropathy and overt proteinuria secondary to type 2 diabetes mellitus.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 08 May 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olmesartan medoxomil (Primary)
Indications Diabetic nephropathies; Proteinuria; Type 2 diabetes mellitus
Focus Adverse reactions; Therapeutic Use
Acronyms ORIENT

Most Recent Events

06 Dec 2011 Actual completion date changed to 01 Feb 2008 after recommendations from IDMC suggested primary endpoint was reached, according to report in Diabetologia.
13 Oct 2011 Results published in the Diabetologia.
01 Jan 2009 Status changed from active, no longer recruiting to completed, as reported by clinicaltrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com